ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

NACompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

February 19, 2024

Study Completion Date

February 19, 2024

Conditions
Alzheimer Disease
Interventions
DEVICE

DBS-f On

Deep Brain Stimulation of the fornix

DEVICE

DBS Off

Deep Brain Stimulation of the fornix turned off

Trial Locations (21)

15212

Allegheny Health Network, Pittsburgh

21224

Johns Hopkins University, Baltimore

27157

Wake Forest Baptist Health, Winston-Salem

32601

University of Florida, Gainesville

33613

University of South Florida, Tampa

63110

Saint Louis University, St Louis

68106

University of Nebraska Medical Center, Omaha

78229

University of Texas Health Sciences Center at San Antonio, San Antonio

78712

University of Texas, Austin

85013

Barrow Neurological Institute, Phoenix

90033

University of Southern California, Los Angeles

94305

Stanford University, Stanford

02903

Rhode Island Hospital, Providence

Unknown

Toronto Western Hospital, Toronto

Universitätmedizin Charité Berlin, Berlin

Universitätklinikum Köln, Cologne

Universitätsklinikum Schleswig Holstein Campus, Kiel

Universität Magdeburg, Magdeburg

Technische Universität München, Munich

Universitätklinikum Würzburg, Würzburg

D-80336

Universitätsklinikum München: Klinik und Poliklinik für Psychiatrie und Psychotherapie Alzheimer Therapie- und Forschungszentrum, München

Sponsors
All Listed Sponsors
lead

Functional Neuromodulation Ltd

INDUSTRY

NCT03622905 - ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease | Biotech Hunter | Biotech Hunter